CI SEC Filing News — The Cigna Group

Latest SEC filings for The Cigna Group (CI) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-09.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, phar…
Sector: Healthcare Industry: Healthcare Plans Market Cap: $79.3B CIK: 1739940
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
10
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for CI currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
CI Filing Activity Snapshot 2026-05-12 — 2026-10-09
Insider Transactions (Form 4)
0 buys vs 5 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$59.11M
Cordani David (Director, Chairman & CEO) · 2026-05-14
201,878 shares · Form 4
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for The Cigna Group.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 5 open-market sale, 4 compensation award and 1 tax withholding. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×5
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×4
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Tax withholding ×1
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Form 4 Open-market sale Insider Selling 2026-09-08

CI insider Neville Everett (See Remarks) sold 617 shares (~$175.3K)

Neville Everett, listed as See Remarks at Cigna Group, reported an open-market sale of 617 CI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 617 $284.05 $175.3K
Filing: Form 4 (Insider Transaction) Insider: Neville Everett (See Remarks) Shares: 617 Est. Value: $175.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-09-03

CI insider Form 4 filed for equity award, exercise, or tax withholding

Evanko Brian C (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 3,113 — —
A Compensation award derivative · Employee Stock Option (Right to Buy) 6,716 — —
Filing: Form 4 (Insider Transaction) Insider: Evanko Brian C (See Remarks) Shares: 3,113
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-09-02

CI insider Form 4 filed for equity award, exercise, or tax withholding

Kurian George (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock Units 108 $276.08 $29.8K
Filing: Form 4 (Insider Transaction) Insider: Kurian George (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-20

CI insider Form 4 filed for equity award, exercise, or tax withholding

Holgerson Bryan (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock Units 0 $291.80 —
A Compensation award derivative · Phantom Stock Units 0 $286.29 —
A Compensation award derivative · Phantom Stock Units 0 $275.25 —
Filing: Form 4 (Insider Transaction) Insider: Holgerson Bryan (See Remarks)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

CI insider Jones Nicole S (See Remarks) sold 2,677 shares (~$748.5K)

Jones Nicole S, listed as See Remarks at Cigna Group, reported an open-market sale of 2,677 CI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,677 $279.61 $748.5K
Filing: Form 4 (Insider Transaction) Insider: Jones Nicole S (See Remarks) Shares: 2,677 Est. Value: $748.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-06

CI insider Jones Nicole S (See Remarks) sold 19,436 shares (~$5.37M)

Jones Nicole S, listed as See Remarks at Cigna Group, reported an open-market sale of 19,436 CI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 14,045 $192.02 $2.70M
S Open-market sale 19,436 $276.27 $5.37M
M Option exercise 1,301 $192.02 $249.8K
M Option exercise derivative · Employee Stock Option (Right to Buy) 14,045 — —
M Option exercise derivative · Employee Stock Option (Right to Buy) 1,301 — —
Filing: Form 4 (Insider Transaction) Insider: Jones Nicole S (See Remarks) Shares: 19,436 Est. Value: $5.37M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-16

CI insider Kates Jamie G (Chief Accounting Officer) sold 899 shares (~$268.5K)

Kates Jamie G, listed as Chief Accounting Officer at Cigna Group, reported an open-market sale of 899 CI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 899 $152.89 $137.5K
S Open-market sale 899 $298.61 $268.5K
M Option exercise derivative · Employee Stock Option (Right to Buy) 899 — —
Filing: Form 4 (Insider Transaction) Insider: Kates Jamie G (Chief Accounting Officer) Shares: 899 Est. Value: $268.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-06-03

CI insider Form 4 filed for equity award, exercise, or tax withholding

Koka Durga Prasad (EVP, Global CIO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 729 $275.53 $200.9K
Filing: Form 4 (Insider Transaction) Insider: Koka Durga Prasad (EVP, Global CIO) Shares: 729
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-02

CI insider Form 4 filed for equity award, exercise, or tax withholding

Kurian George (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Phantom Stock Units 108 $277.40 $30.0K
Filing: Form 4 (Insider Transaction) Insider: Kurian George (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-14

CI insider Cordani David (Director, Chairman & CEO) sold 201,878 shares (~$59.11M)

Cordani David, listed as Director, Chairman & CEO at Cigna Group, reported an open-market sale of 201,878 CI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 103,595 $149.13 $15.45M
M Option exercise 85,519 $197.35 $16.88M
S Open-market sale 3,903 $286.83 $1.12M
S Open-market sale 14,292 $287.96 $4.12M
S Open-market sale 13,839 $288.85 $4.00M
S Open-market sale 41,099 $290.00 $11.92M
S Open-market sale 13,732 $291.01 $4.00M
S Open-market sale 12,315 $291.95 $3.60M
S Open-market sale 7,861 $292.88 $2.30M
S Open-market sale 2,142 $293.92 $629.6K
S Open-market sale 38,487 $294.98 $11.35M
S Open-market sale 34,641 $295.98 $10.25M
S Open-market sale 2,017 $296.84 $598.7K
S Open-market sale 15,319 $298.24 $4.57M
S Open-market sale 2,231 $298.53 $666.0K
M Option exercise 15,458 $149.13 $2.31M
M Option exercise 7,971 $197.35 $1.57M
M Option exercise derivative · Employee Stock Option (Right to Buy) 103,595 — —
M Option exercise derivative · Employee Stock Option (Right to Buy) 15,458 — —
M Option exercise derivative · Employee Stock Option (Right to Buy) 85,519 — —
M Option exercise derivative · Employee Stock Option (Right to Buy) 7,971 — —
Filing: Form 4 (Insider Transaction) Insider: Cordani David (Director, Chairman & CEO) Shares: 201,878 Est. Value: $59.11M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. The Cigna Group has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-03

CI Form 144 filed for proposed insider sale by Neville Everett (617 shares) ~$175.3K

Neville Everett filed a Form 144 with the SEC indicating intent to sell CI (Cigna Group) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Neville Everett Shares: 617 Est. Value: $175.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-18

CI Form 144 filed for proposed insider sale by Jones Nicole S (2,677 shares) ~$748.4K

Jones Nicole S filed a Form 144 with the SEC indicating intent to sell CI (Cigna Group) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jones Nicole S Shares: 2,677 Est. Value: $748.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-04

CI Form 144 filed for proposed insider sale by Jones Nicole S (19,436 shares) ~$5.37M

Jones Nicole S filed a Form 144 with the SEC indicating intent to sell CI (Cigna Group) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Jones Nicole S Shares: 19,436 Est. Value: $5.37M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-12

CI Form 144 filed for proposed insider sale by Kates Jamie G (899 shares) ~$268.5K

Kates Jamie G filed a Form 144 with the SEC indicating intent to sell CI (Cigna Group) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Kates Jamie G Shares: 899 Est. Value: $268.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-05-12

CI Form 144 filed for proposed insider sale by Cordani David (201,878 shares) ~$59.11M

Cordani David filed a Form 144 with the SEC indicating intent to sell CI (Cigna Group) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Cordani David Shares: 201,878 Est. Value: $59.11M
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for The Cigna Group. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-09

CI filed 8-K — material company event

Cigna Group filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-30

CI filed 8-K — material company event

Cigna Group filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-30

CI filed 8-K — material company event

Cigna Group filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-13

CI filed 8-K — material company event

Cigna Group filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for The Cigna Group.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

CI filed Quarterly Report (10-Q)

Cigna Group filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify The Cigna Group's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CI. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CI SEC Filings

More Tools for CI

CI Full Stock Analysis CI Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CI analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CI stock analysis page.

CI Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer